Work

Real-world use and outcomes of darolutamide (DARO), enzalutamide (ENZA), and apalutamide (APA) for nonmetastatic castration-resistant prostate cancer (nmCRPC): Race subgroup analysis.

Year: 2025

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2025.43.5_suppl.158

Authors: Daniel J. George, Alicia K. Morgans, Nasreen Khan, Niculae Constantinovici, Guifang Chen, Mercedeh Ghadessi, Vlasta Hlebec, Neal D. Shore

Institutions: Duke University, Duke Cancer Institute, Dana-Farber Cancer Institute, Bayer (United States), Bayer (Switzerland), Carolina Urologic Research Center

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDGs: Good health and well-being, Reduced inequalities

Open Access status: closed

Funder: Bayer

OpenAlex ID: W4407701184

Cites:

Cited by:

Related to: 10